A $90B industry being regulated in real time — with no shared source of truth. One regulatory-intelligence graph powering AI engines for compliance
The intelligence layer gets built once. Whoever builds it now, owns it.
Noocyte is not three products — it's one operating system. A shared intelligence graph underneath, with an engine for every stakeholder above.
Scan any claim, product, or clinic for enforcement risk — a live enforcement feed, a 21 CFR 1271.10(a) four-prong classifier, company risk boards, Claim Clearance™ + an Enforcement Risk Score™.
The enterprise system of record for HCT/P & cell therapy — a counsel co-signed, cryptographically signed audit trail licensed portfolio-wide by tissue companies, CGT sponsors, and law firms.
Cited, evidence-based regenerative-medicine guidance — in any language, including Arabic — so patients and practitioners can make informed decisions and verify a clinic before they act.
An AI watchdog that publicly flags adulterated products and bad actors — protecting patients, feeding the graph, and driving distribution across the ecosystem.
A believable path: prove the wedge, expand the enterprise motion, then compound. Targets, not results.
Bloomberg has finance. LexisNexis has law. FDA.gov and ClinicalTrials.gov hold the raw data. The top-right — domain-specific intelligence that is actually actionable — is empty. Noocyte combines what all of them do, for the one industry that needs it most.
Noocyte Inc. is the parent company behind BioIntelScan, BioIntel.io, and CellIntel.ai.
Serial entrepreneur and builder who scaled the Viva Vision mobile-TV platform (2008 Inc. 500 top-5) and architected and built all three of Noocyte's live products. He operates BioRegenEx, an active regenerative-medicine business — so he lives the customer's problem.
Principal of Hillman Ventures — three decades in FDA-regulated healthcare, with 89+ ventures co-founded and 85+ strategic exits. Brings deep regenerative-medicine, regulatory-strategy, and capital-markets expertise.
For clinics, manufacturers, investors, law firms, and partners who need to know what's compliant, real, and safe.